New approaches to curb developmental and end-stage production expenses, whilst generating a safe and effective treatment for cancer, resulting in lower cost for the patient and healthcare system, are warranted. A bioassay-guided fractionation of a Solanum plant, S. sodomaeum, to a standardized extract can be classified as a new drug. It is shown that a specific standardized plant extract, BEC, containing a given concentration of a target efficacious and safe compound, solamargine, is an acceptable anticancer and less costly chemotherapeutic reality.
Solasodine rhamnosides produced in plants as secondary metabolites, are safe and effective when treating a variety of cancers, including non-melanoma skin cancers. They are cytotoxic against multi-drug resistant tumor cells, stimulate lasting immunity against cancer, are not mutagenic and display anti-mutagenic properties. These antineoplastics, through cellular specific receptor-mediated actions, directly induce apoptosis by triggering extrinsic and intrinsic apoptotic pathways in cancer cells but not normal cells. Curaderm BEC5 contains solasodine rhamnosides and is a topical formulation for the treatment of keratoses and non-melanoma skin cancers. The mode of action, together with the selectivity towards cancer cells, with Curaderm BEC5 therapy, results in outstanding beneficial outcomes. This study shows graphically and pictorially that Curaderm BEC5 seeks and destroys basal cell carcinoma whilst normal skin cells replace the dead cancer cells during therapy, emanating into impressive cosmetic end results. The clinical observations with Curaderm BEC5 therapy reveal that initially the lesion size increases over four-fold due to the interaction of Curaderm BEC5 with deeper and more lateral tumor cells, followed by a decrease in size, ultimately, resulting in complete elimination of the basal cell carcinoma.
Dermatologists, surgeons, oncologists and radiotherapists usually jointly manage skin cancers. The strengths and limitations of the established procedures are known. A new naturally derived topical cream, Curaderm BEC5 , for the treatment of non melanoma skin cancers has previously been described. In this communication, intra-comparison treatments of skin cancer between Curaderm BEC5 therapy and the established treatments, surgery, radiation therapy, laser therapy, photodynamic therapy, imiquimod cream and cryosurgery are presented. Non melanoma skin cancer cases that had previously been treated unsuccessfully with the established procedures were subsequently treated successfully with Curaderm BEC5. These observations are interesting because the identical lesions were treated by various modalities. In addition to the superior efficacious outcome of Curaderm BEC5 therapy versus the established treatments, the cosmetic end results with Curaderm BEC5 treatment are remarkable.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.